Nasdaq Biotech Index Higher As GPC Biotech, Spectrum, Pharmion Lead
The NBI gained almost 0.80% on the day as news of the Satraplatin phase 3 study skyrocketed the share prices of all three companies involved in the development and marketing of the drug for prostate cancer.
Spectrum (SPPI) is developing the drug and is partnered with GPC Biotech (GPCB) for marketing, and in turn Pharmion (PHRM) has licensed the rights to sell Satraplatin in Europe.
SPPI +45.56%
GPCB +34.07%
PHRM +19.99%
_
The NBI gained almost 0.80% on the day as news of the Satraplatin phase 3 study skyrocketed the share prices of all three companies involved in the development and marketing of the drug for prostate cancer.
Spectrum (SPPI) is developing the drug and is partnered with GPC Biotech (GPCB) for marketing, and in turn Pharmion (PHRM) has licensed the rights to sell Satraplatin in Europe.
SPPI +45.56%
GPCB +34.07%
PHRM +19.99%
_
posted by Nico at
6:20 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home